Johnson & Johnson, which has lost hundreds of millions of dollars in jury awards over its Ethicon pelvic mesh products, scored its third defense verdict in 2022.

The July 1 verdict from a federal jury in Denver follows two other defense verdicts in March, one in Arizona and the other in West Virginia. This year’s victories contrast with Ethicon pelvic mesh trials that occurred prior to the COVID-19 pandemic, when juries awarded between $2.1 million to $120 million to plaintiffs.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]